Recent Work
  • Clementia Pharmaceuticals Inc., as Canadian counsel, in connection with the proposed friendly acquisition by Ipsen S.A. of Clementia Pharmaceuticals by way of court-approved a plan of arrangement for an initial aggregate consideration of US$1B, plus deferred payments on the achievement of a future regulatory milestone in the form of a contingent value right (CVR) of US$6.00 per share upon FDA acceptance of the NDA filing for palovarotene for the treatment of MO, representing an additional potential payment of US$263M.
  • Akumin Inc. in connection with its transactions to acquire Advanced Diagnostics Group, The Imaging Centers of West Palm and management of Elite Radiology of Georgia. As a result of the closing, Akumin indirectly acquired all of the issued and outstanding equity interests of ADG Acquisition Holdings, Inc., TIC Acquisition Holdings, LLC and SFL Radiology Holdings, LLC. The total purchase price for the Targets was approximately US$214M of which US$25M was satisfied by the issuance of Akumin shares.
  • SBI ALApharma Canada Inc., a subsidiary of Germany-based Photonamic GmbH & Co. and SBI ALApharma Limited, in SBI's purchase of the clinical oncology business of Toronto-based Moleculight Inc. as well as licensing arrangements with the University Health Network.
  • Curaleaf Holdings, Inc. in its acquisition of the state-regulated cannabis business of Cura Partners, Inc. in an all-stock transaction valued at approximately C$1.3B.
  • Repare Therapeutics Inc., as lead counsel, in its US$82.5M Series B financing. Repare is a Montréal-based biotech company that is in the early stages of “precision oncology” drugs that attack genetic defects in certain cancerous tumours. The financing was led by a strong syndicate of U.S. and Canadian investors that included Cowen Healthcare Investments, OrbiMed, Redmile, BVF Partners LP and Logos Capital (new investors) as well as Repare’s early investors Versant Ventures, MPM Capital, Fonds de solidarité FTQ and BDC Capital.
  • JAMP Pharma, providing ongoing advisory work including assisting with: all drug licensing; regulatory approvals; commercial agreements; clinical trial agreements; product development agreements; sales representation agreements; financing; litigation.
  • Laboratory Corporation of America, as Canadian Counsel, in its US$1.2B share acquisition of Chiltern International Group Limited.
  • Norgine B.V. in its acquisition of all of the issued and outstanding common shares of Merus Labs International Inc for approximately C$342M.
  • A clinical stage company that is researching and developing novel vaccine therapies in the drafting of research and development agreements, service agreements and material transfer agreements with universities worldwide, research institutes and government entities, such as Canada’s National Research Council.
  • Akumin Inc. in connection with an initial public offering of common shares issuable without payment upon the deemed exercise of previously issued special warrants.
  • Kilmer Capital Partners Limited in the sale of Altasciences Company Inc., formerly known as Algorithme Pharma Inc., to the Audax Group.
  • ProMetic Life Sciences Inc. in its acquisition of Telesta Therapeutics Inc., a Montréal-based biotechnology company focused on the licensing, acquisition and development of transformational therapeutics for the treatment of serious human diseases such as cancer, immune diseases and targeted rare diseases.
  • The Persistence Capital Partners group, a Canadian private equity firm exclusively focused in healthcare, in transactions with: Anima-Plus Group Inc., Quebec’s leading group of veterinary services providers; LMC Diabetes & Endocrinology, Canada’s leading national diabetes, endocrinology and metabolic disease practice; Plexo Medical Centre, a Quebec-based provider of corporate health services; Copeman Healthcare Inc., a Vancouver-based provider of health services; mdBriefCase Group Inc., Canada and Australia's leading provider of online continuing health education.
  • Tenex Capital Partners, L.P., an operationally focused private equity firm, as Canadian counsel, in its acquisition of the assets of Ohio Medical Corporation from MVC Capital Inc. Ohio Medical Corporation is a market leading manufacturer and distributor of medical suction and oxygen therapy products and source equipment.
  • Dynacare, one of Canada’s largest laboratory services and solutions providers, in a series of strategic acquisitions in various provinces including Lab Bio-Médic, a privately owned laboratory in Quebec that provides services to medical clinics, industries, insurance companies and clinical research organizations; (ii) MedAxio Insurance Medical Services and Warnex Medical Laboratories.
  • A private equity firm in a partnership between IntegraMed Fertility and Groupe OPMEDIC, leading networks of fertility clinics in the United States and Canada, a transaction designed to increase the level of investment and resources available to doctors and patients to deliver outstanding patient outcomes and care.
  • Nordion Inc. in its US$727M acquisition by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.
  • Actavis plc, as Canadian counsel, in two separate transactions: (i) the acquisition by AstraZeneca of Actavis’ branded respiratory business; (ii) the acquisition by TPG of Actavis’ Pharmatech business, a pharmaceutical outsourcing and R&D business within Actavis’ subsidiary Aptalis.
  • Allergan Inc., maker of the Botox wrinkle treatment, as Canadian counsel in its US$66B sale to Actavis plc.
  • Lasik MD Inc. in connection with the C$25M initial investment in Lasik by Caisse de dépôt et placement du Québec as part of Lasik’s long-term financing strategy to assist it in pursuing international acquisitions.
  • LabCorp in its US$6.1B acquisition of Covance, a global drug development services company.